HEALTHMEDPAGE TODAY
FDA Issues Safety Alert on Weight-Loss Drug's Kidney Risks
The FDA issued a safety alert regarding the over-the-counter weight-loss drug orlistat (alli), warning of potential kidney stone and kidney injury risks. The agency approved a label change to include these warnings.
Related Signal
Adjacent reporting
- Telehealth Booms as Demand for GLP-1s Surges and Questions Mount About Safety, Oversight
- FDA asks Lilly for more safety data on weight loss pill Foundayo
- Hims Sales Miss on Rising Competition for Weight-Loss Drugs
- STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
- CVS Caremark will cover Lilly’s weight loss drug Zepbound again after patient backlash
- Patients taking weight-loss drugs often make 5 critical mistakes, doctor warns